BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

This study tests a new drug called BOLD-100 in combination with a standard chemotherapy regimen called FOLFOX for patients with advanced gastrointestinal cancers (such as colorectal, stomach, or pancreatic cancer) that have spread or cannot be removed with surgery. **You may be eligible if...** - You are 18 or older - You have a gastrointestinal cancer that has spread or cannot be surgically removed, confirmed by biopsy - You have measurable disease on scans - You are in good health (ECOG 0–1) and have adequate organ function - For one specific treatment arm: you have received only 1 prior treatment and your tumor does not have a BRAF mutation **You may NOT be eligible if...** - You have nerve damage worse than grade 2 - You previously could not tolerate fluorouracil (5-FU) or oxaliplatin (components of FOLFOX) - You have cancer in the brain or spinal fluid - You had a stroke in the past 6 months - You have serious heart disease or recent internal bleeding Talk to your doctor to see if this trial is right for you.